Related references
Note: Only part of the references are listed.A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism
Nuria Gonzalez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Cross-Reactive Neutralizing Humoral Immunity Does Not Protect from HIV Type 1 Disease Progression
Zelda Euler et al.
JOURNAL OF INFECTIOUS DISEASES (2010)
Breadth of Human Immunodeficiency Virus-Specific Neutralizing Activity in Sera: Clustering Analysis and Association with Clinical Variables
Nicole A. Doria-Rose et al.
JOURNAL OF VIROLOGY (2010)
Crystal Structure of PG16 and Chimeric Dissection with Somatically Related PG9: Structure-Function Analysis of Two Quaternary-Specific Antibodies That Effectively Neutralize HIV-1
Marie Pancera et al.
JOURNAL OF VIROLOGY (2010)
Heterogeneous neutralizing antibody and anti body-dependent cell cytotoxicity responses in HIV-1 elite controllers
Olivier Lambotte et al.
AIDS (2009)
HIV-1 Envelope Induces Memory B Cell Responses That Correlate with Plasma Antibody Levels after Envelope gp120 Protein Vaccination or HIV-1 Infection
Mattia Bonsignori et al.
JOURNAL OF IMMUNOLOGY (2009)
Frequency and Phenotype of Human Immunodeficiency Virus Envelope-Specific B Cells from Patients with Broadly Cross-Neutralizing Antibodies
Nicole A. Doria-Rose et al.
JOURNAL OF VIROLOGY (2009)
Factors Associated with the Development of Cross-Reactive Neutralizing Antibodies during Human Immunodeficiency Virus Type 1 Infection
D. Noah Sather et al.
JOURNAL OF VIROLOGY (2009)
Continuous Viral Escape and Selection by Autologous Neutralizing Antibodies in Drug-Naive Human Immunodeficiency Virus Controllers
Madhumita Mahalanabis et al.
JOURNAL OF VIROLOGY (2009)
Antibody Specificities Associated with Neutralization Breadth in Plasma from Human Immunodeficiency Virus Type 1 Subtype C-Infected Blood Donors
Elin S. Gray et al.
JOURNAL OF VIROLOGY (2009)
Human Immunodeficiency Virus Type 1 Elite Neutralizers: Individuals with Broad and Potent Neutralizing Activity Identified by Using a High-Throughput Neutralization Assay together with an Analytical Selection Algorithm
Melissa D. Simek et al.
JOURNAL OF VIROLOGY (2009)
Breadth of Neutralizing Antibody Response to Human Immunodeficiency Virus Type 1 Is Affected by Factors Early in Infection but Does Not Influence Disease Progression
Anne Piantadosi et al.
JOURNAL OF VIROLOGY (2009)
Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
Johannes F. Scheid et al.
NATURE (2009)
Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs
Mayte Coiras et al.
NATURE REVIEWS MICROBIOLOGY (2009)
International Network for Comparison of HIV Neutralization Assays: The NeutNet Report
Eva Maria Fenyo et al.
PLOS ONE (2009)
B cells in HIV infection and disease
Susan Moir et al.
NATURE REVIEWS IMMUNOLOGY (2009)
Relationship between T cell activation and CD4(+) T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy
Peter W. Hunt et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Normalization of B cell counts and subpopulations after antiretroviral therapy in chronic HIV disease
Susan Moir et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy
Florencia Pereyra et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Identification of Gammaretroviruses Constitutively Released from Cell Lines Used for Human Immunodeficiency Virus Research
Yasuhiro Takeuchi et al.
JOURNAL OF VIROLOGY (2008)
Profiling the Specificity of Neutralizing Antibodies in a Large Panel of Plasmas from Patients Chronically Infected with Human Immunodeficiency Virus Type 1 Subtypes B and C
James M. Binley et al.
JOURNAL OF VIROLOGY (2008)
High level serum neutralizing antibody against HIV-1 in Chinese long-term non-progressors
Qian Wang et al.
MICROBIOLOGY AND IMMUNOLOGY (2008)
Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy
Sarah Palmer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
B cell immunopathology during HIV-1 infection: Lessons to learn for HIV-1 vaccine design
Alberto Cagigi et al.
VACCINE (2008)
Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers
Shixia Wang et al.
VACCINE (2008)
ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia
Frank Maldarelli et al.
PLOS PATHOGENS (2007)
Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma
Michael Humbert et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2007)
A new strategy based on recombinant viruses as a tool for assessing drug susceptibility of human immunodeficiency virus type 1
J. Garcia-Perez et al.
JOURNAL OF MEDICAL VIROLOGY (2007)
Balancing selection and the evolution of functional polymorphism in Old World monkey TRIM5α
Ruchi M. Newman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Loss of memory B cells impairs maintenance of long-term serologic memory during HIV-1 infection
Kehmia Titanji et al.
BLOOD (2006)
Efavirenz in plasma from HIV-infected patients does not directly block reverse transcriptase activity in cell-free assays but inhibits HIV replication in cellular assays
Renaud Burrer et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2006)
Residual human immunodeficiency virus type 1 viremia in some patients on Antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells
JR Bailey et al.
JOURNAL OF VIROLOGY (2006)
Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations
Justin R. Bailey et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2006)
Vpr and HIV-1 disease progression: R77Q mutation is associated with long-term control of HIV-1 infection in different groups of patients
D Mologni et al.
AIDS (2006)
Neutralizing antibody responses against autologous and heterologous viruses in acute versus chronic human immunodeficiency virus (HIV) infection: Evidence for a constraint on the ability of HIV to completely evade neutralizing antibody responses
Steven G. Decks et al.
JOURNAL OF VIROLOGY (2006)
Natural controlled HIV infection: Preserved HIV-specific immunity despite undetectable replication competent virus
N Kloosterboer et al.
VIROLOGY (2005)
Evidence that low-level viremias during effective highly active antiretroviral therapy result from two processes: Expression of archival virus and replication of virus
NH Tobin et al.
JOURNAL OF VIROLOGY (2005)
Intermittent HIV-1 viremia (blips) and drug resistance in patients receiving HAART
RE Nettles et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Genotypic analysis of HIV-1 drug resistance at the limit of detection: Virus production without evolution in treated adults with undetectable HIV loads
TL Kieffer et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Mechanisms of hypergammaglobulinemia and impaired antigen-specific humoral immunity in HIV-1 infection
A De Milito et al.
BLOOD (2004)
Global strategies to prevent bacterial pneumonia in adults with HIV disease
DR Feikin et al.
LANCET INFECTIOUS DISEASES (2004)
Continued production of drug-sensitive human immunodeficiency virus type 1 in children on combination antiretroviral therapy who have undetectable viral loads
D Persaud et al.
JOURNAL OF VIROLOGY (2004)
Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years
DV Havlir et al.
JOURNAL OF VIROLOGY (2003)
First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection
B Wang et al.
VIROLOGY (2003)
Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals
PWG Mallon et al.
JOURNAL OF CLINICAL VIROLOGY (2003)
HIV-specific CD8+ T cell proliferation is coupled to perforin expression and is maintained in nonprogressors
SA Migueles et al.
NATURE IMMUNOLOGY (2002)
Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
XP Wei et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
G Stiegler et al.
AIDS RESEARCH AND HUMAN RETROVIRUSES (2001)
Prevalence and predictive value of intermittent viremia with combination HIV therapy
DV Havlir et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/mL receiving combination therapy
M Hermankova et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients
R Burrer et al.
JOURNAL OF VIROLOGY (2001)
Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
C Marzolini et al.
AIDS (2001)
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120
CA Derdeyn et al.
JOURNAL OF VIROLOGY (2000)
HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors
SA Migueles et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Share Paper
